title: Therapeutic particularities in amiodarone induced thyroid disorder in patients with underlying cardiac condition.
abstract: OBJECTIVE
  the analysis of therapeutic approach in patients with basic heart condition and amiodarone induced thyroid dysfunction--correlations with the evolution and prognosis.
  
  
  METHODS
  The study included 215 patients, 90 men and 125 women aged between 35 and 87, with different cardiac pathologies hospitalized in the Cardiology Clinic between 2004-2014, who received amiodarone treatment, in most cases for prophylaxis of various arrhythmias, both supraventricular and ventricular. During the evolution, these patients have developed amiodarone-induced thyroid dysfunction (hypo- or hyper function).
  
  
  CONCLUSIONS
  The evaluation of thyroid function after starting treatment was performed in 187 patients (86.97%). Diagnosis of amiodarone-induced thyroid dysfunction was based on hormonal dosages of TSH, FT4 and FT3, endocrinological examination and thyroid ultrasound. Thyroid dysfunction treatment was initiated, depending on the situation, in all patients during the hospitalization. Treatment included anti thyroid drugs or hormones substitution and in some cases a minimal dose of prednisone.
  
  
  CONCLUSIONS
  Thyroid dysfunction regardless of the type (with hypo- or hyper function) requires continuous changes of the cardiovascular treatment, and association, where appropriate, with thyroid dysfunction medication. In some cases the latter determines cardiovascular side effects, for instance corticotheraphy may become a factor of imbalance for the hemodynamic status of the patient (by fluid retention, increased blood pressure, hyper glycemia).
authors.affiliation: University of Medicine and Pharmacy Grigore T. Popa - Iaşi, Department of Medical Specialties (I).
authors.forename: Luliana
authors.initials: L
authors.lastname: Costache
authors.forename: Voichiţa
authors.initials: V
authors.lastname: Mogos
authors.forename: Cristina
authors.initials: C
authors.lastname: Preda
authors.forename: Carmen
authors.initials: C
authors.lastname: Vulpoi
authors.forename: Maria-Christina
authors.initials: MC
authors.lastname: Ungureanu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000638:Amiodarone / Q000009:adverse effects* / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D015415:Biomarkers / Q000097:blood; D002309:Cardiology; D005260:Female; D006801:Humans; D007037:Hypothyroidism / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011379:Prognosis; D012189:Retrospective Studies; D012383:Romania / Q000453:epidemiology; D013959:Thyroid Diseases / Q000139:chemically induced; D013971:Thyrotoxicosis / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000097:blood
chemical_list: D000889:Anti-Arrhythmia Agents; D015415:Biomarkers; D014284:Triiodothyronine; D013972:Thyrotropin; D000638:Amiodarone; D013974:Thyroxine